Cargando…

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer

BACKGROUND: This study was intended to determine the clinical significance of circulating tumour cells (CTCs) in patients with advanced gastric cancer (AGC), particularly the potential role of CTCs for dynamic monitoring of the therapeutic response. METHODS: A single-centre, prospective study was un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yilin, Gong, Jifang, Zhang, Qiyue, Lu, Zhihao, Gao, Jing, Li, Yanyan, Cao, Yanshuo, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815805/ https://www.ncbi.nlm.nih.gov/pubmed/26784122 http://dx.doi.org/10.1038/bjc.2015.417

Ejemplares similares

Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2014)

Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer
por: Chen, Yang, et al.
Publicado: (2021)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
por: Chen, Zuhua, et al.
Publicado: (2022)

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment
por: Chen, Yang, et al.
Publicado: (2022)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Tian, Tiantian, et al.
Publicado: (2016)

A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer
por: Zhang, Qiyue, et al.
Publicado: (2018)

Long-term prognostic impact of circulating tumour cells in gastric cancer patients
por: Ito, Hiroaki, et al.
Publicado: (2016)

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
por: Liu, Dan, et al.
Publicado: (2023)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
por: Xie, Tong, et al.
Publicado: (2020)

Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance?
por: Lu, Zhihao, et al.
Publicado: (2014)

Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer
por: Tang, Rui, et al.
Publicado: (2023)

Autophagy inhibition enhances PD-L1 expression in gastric cancer
por: Wang, Xiaojuan, et al.
Publicado: (2019)

Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer
por: Chen, Zuhua, et al.
Publicado: (2019)

Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer
por: Gao, Jing, et al.
Publicado: (2017)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers
por: Takakura, M, et al.
Publicado: (2012)

Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer
por: Wang, Jun-Ping, et al.
Publicado: (2023)

Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer
por: Shen, Feifei, et al.
Publicado: (2021)

Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study
por: Wang, Xicheng, et al.
Publicado: (2017)

Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours
por: Li, Yuan-Liang, et al.
Publicado: (2020)

Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics
por: Zhong, Fengyun, et al.
Publicado: (2023)

Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging
por: Willecke-Hochmuth, Regina, et al.
Publicado: (2016)

Correction to: Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics
por: Zhong, Fengyun, et al.
Publicado: (2023)

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
por: Yamanaka, T, et al.
Publicado: (2007)

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
por: Thuss-Patience, P C, et al.
Publicado: (2011)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
por: Liu, Ying, et al.
Publicado: (2013)

A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor
por: Zhang, Qi, et al.
Publicado: (2022)

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
por: Zhou, Nan, et al.
Publicado: (2023)

Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer
por: Zhang, Caihua, et al.
Publicado: (2012)

Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study
por: Bork, U, et al.
Publicado: (2015)

Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer
por: Demark-Wahnefried, Wendy, et al.
Publicado: (2017)

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial
por: Lu, Zhihao, et al.
Publicado: (2021)

Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
por: Martin-Liberal, J, et al.
Publicado: (2014)

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
por: Zhou, Xinping, et al.
Publicado: (2023)

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
por: Zhu, M, et al.
Publicado: (2015)

The measurement and therapeutic implications of circulating tumour cells in breast cancer
por: Smerage, J B, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_bue99aecmtjodnuhvmu0bvj705